OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 727-736
Open Access | Times Cited: 16
Douglas A. Rubinson, Noritaka Tanaka, Ferran Fece de la Cruz, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 727-736
Open Access | Times Cited: 16
Showing 16 citing articles:
If it’s a target, it’s a pan-cancer target: Tissue is not the issue
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11
Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, et al.
Cancer Treatment Reviews (2024) Vol. 125, pp. 102721-102721
Open Access | Times Cited: 11
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
Jakob M. Riedl, Ferran Fece de la Cruz, W. Marston Linehan, et al.
Annals of Oncology (2025)
Open Access | Times Cited: 1
KRAS inhibitors: resistance drivers and combinatorial strategies
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Tamara Isermann, Christine Sers, Channing J. Der, et al.
Trends in cancer (2024)
Open Access | Times Cited: 6
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Peiyuan Yang, Yongchao Li
Investigational New Drugs (2025)
Closed Access
Treatment options for KRAS G12C mutated metastatic colorectal cancer
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Marián Liberko
Onkologie (2025) Vol. 19, Iss. 1, pp. 33-36
Closed Access
Crystal structure of NRAS Q61K with a ligand-induced pocket near switch II
Teklab Gebregiworgis, Jonathan Yui-Lai Chan, D.A. Kuntz, et al.
European Journal of Cell Biology (2024) Vol. 103, Iss. 2, pp. 151414-151414
Open Access | Times Cited: 2
Teklab Gebregiworgis, Jonathan Yui-Lai Chan, D.A. Kuntz, et al.
European Journal of Cell Biology (2024) Vol. 103, Iss. 2, pp. 151414-151414
Open Access | Times Cited: 2
Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
Randa Mahran, Jonas N. Kapp, Salla Valtonen, et al.
ACS Chemical Biology (2024) Vol. 19, Iss. 10, pp. 2152-2164
Closed Access | Times Cited: 2
Precision Oncology: 2024 in Review
Matteo Repetto, Nicole Fernandez, Alexander Drilon, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2332-2345
Closed Access | Times Cited: 2
Matteo Repetto, Nicole Fernandez, Alexander Drilon, et al.
Cancer Discovery (2024) Vol. 14, Iss. 12, pp. 2332-2345
Closed Access | Times Cited: 2
The Target Therapy Hyperbole: “KRAS (p.G12C)”—The Simplification of a Complex Biological Problem
Massimiliano Chetta, Anna Basile, Marina Tarsitano, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2389-2389
Open Access | Times Cited: 1
Massimiliano Chetta, Anna Basile, Marina Tarsitano, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2389-2389
Open Access | Times Cited: 1
RAS G12C Inhibitors: Three Birds with One Stone
Tessa Seale, Sandra Misale
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 698-700
Closed Access | Times Cited: 1
Tessa Seale, Sandra Misale
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 698-700
Closed Access | Times Cited: 1
Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches
Neiha Kidwai, Monica F. Chen, Michael A. Postow, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Neiha Kidwai, Monica F. Chen, Michael A. Postow, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Combinations of RAS pathway inhibitors with targeted agents are active in spheroids of patient-derived cells with oncogenic KRAS variants from multiple cancer types
Zahra Davoudi, Thomas S. Dexheimer, Nathan P. Coussens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Zahra Davoudi, Thomas S. Dexheimer, Nathan P. Coussens, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Targeting undruggable protein KRAS for cancer therapy: novel opportunities and challenges
Xin Yang, Xiang Li, Yuelin Zhang, et al.
Future Medicinal Chemistry (2024), pp. 1-5
Closed Access
Xin Yang, Xiang Li, Yuelin Zhang, et al.
Future Medicinal Chemistry (2024), pp. 1-5
Closed Access
Mechanisms of Resistance to KRAS Inhibitors: Cancer Cells' Strategic Use of Normal Cellular Mechanisms to Adapt
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
Noritaka Tanaka, Hiromichi Ebi
Cancer Science (2024)
Open Access
De novodesign of Ras isoform selective binders
Jason Z. Zhang, Xinting Li, Alexa Rane Batingana, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Jason Z. Zhang, Xinting Li, Alexa Rane Batingana, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Fiona Healy, Amy L. Turner, Vanessa Marensi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Fiona Healy, Amy L. Turner, Vanessa Marensi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
